2月12日主力资金净流出130.92万元，散户资金则呈现小幅流入，反映出当前市场存在一定分歧。 经济观察网嘉华股份（603182）近7日股价呈现震荡走势，区间微跌0.12%，振幅4.62%。2月9日股价上 涨1.78%，成交活跃，随后几个交易日小幅回调，截至2月12日收盘报16.20元，当日下跌1.16%。技术面 上，股价在布林带中轨附近波动，短期动能偏弱。资金流向显示，2月12日主力资金净流出130.92万 元。 股票近期走势 股价在20日布林带中轨(16.15元)附近波动，上方压力位关注16.54元，下方支撑位参考15.72元。MACD 指标显示短期动能偏弱，但整体仍处于震荡区间。 资金走向 板块变化情况 同期，公司所属的农林牧渔板块整体下跌1.49%，农产品加工板块下跌1.11%，公司股价表现略强于行 业平均水平。 以上内容基于公开资料整理，不构成投资建议。 ...

Core Viewpoint - Jia Hua Co., Ltd. has shown a stable stock price trend with an increase of over 50% in the past year, but is currently facing a period of consolidation and direction selection [1][10]. Group 1: Stock Performance - Since its listing in September 2022, Jia Hua's stock has experienced a slight decline in performance, with a total market capitalization of 2.725 billion yuan as of February 9 [2][11]. - After reaching a low point in February 2024, the stock has rebounded, showing a strong performance with a 56.67% increase from January 6, 2025, to the present [2][11]. - The stock has been in a consolidation phase for the last 60 trading days, indicating uncertainty in its future direction [3][12]. Group 2: Business Overview - Jia Hua primarily engages in the research, production, and sales of soybean protein and related by-products, sourcing non-GMO soybeans from farmers and distributors [4][13]. - The company's products are utilized across various sectors, including meat products, snack foods, dairy products, nutritional supplements, hot pot ingredients, baked goods, pet food, specialized medical diets, and pharmaceuticals [4][13]. Group 3: Market and Financial Performance - The company has a broad sales market covering nearly 100 countries and regions, including the EU, the USA, Australia, and Japan [5][14]. - For the first three quarters of 2025, Jia Hua reported operating revenue of 1.027 billion yuan, a year-on-year decrease of 7.19%, while net profit was 82.173 million yuan, an increase of 7.46% [5][14]. - Over the three years since its listing, the company's operating revenue has shown a decline from 1.613 billion yuan in 2022 to 1.488 billion yuan in 2024, with net profits slightly decreasing from 114 million yuan to 109 million yuan [5][14]. Group 4: Future Growth Expectations - The company is expected to see growth in 2025 as its production capacity is set to be released, with three new projects expected to be completed by the end of 2024 and gradually operational in the first half of 2025 [7][17]. - The recovery of downstream industries, such as meat and snack foods, is anticipated to enhance the company's performance [8][17]. - Jia Hua has established a strong relationship with major client Anjiyuan Food, which has recently become one of its top ten shareholders, holding 3.51% of the total shares [9][18].

Core Viewpoint - Jia Hua Co., Ltd. (603182) indicates that its overseas market, including the EU and nearly 100 countries and regions globally, will account for 35.22% of its operating revenue in 2024, with an expected increase to 36.60% by the third quarter of 2025 [1] Group 1 - The company has a significant presence in the overseas market, particularly in the EU, which is one of its main international markets [1] - The primary sales method for the company is direct exports from domestic entities to the EU market [1]

Group 1 - The core point of the article highlights the recent stock performance of JiaHua Co., which saw a decline of 2.06% on December 26, with a current share price of 16.16 yuan and a market capitalization of 2.659 billion yuan [1] - JiaHua Co. has experienced a year-to-date stock price increase of 45.45%, with a 1.25% rise over the last five trading days, a 0.37% increase over the last 20 days, and an 18.48% rise over the last 60 days [1] - The company, established on December 8, 2000, specializes in the research, production, and sales of soybean protein, with its main revenue sources being soybean protein (58.07%), soybean oil (21.94%), and dietary fiber (6.11%) [1] Group 2 - As of September 30, the number of shareholders for JiaHua Co. was 8,539, a decrease of 16.63% from the previous period, while the average circulating shares per person increased by 112.04% to 19,270 shares [1] - For the period from January to September 2025, JiaHua Co. reported a revenue of 1.027 billion yuan, a year-on-year decrease of 7.19%, while the net profit attributable to the parent company was 82.173 million yuan, reflecting a year-on-year increase of 7.46% [1] - The company has distributed a total of 181 million yuan in dividends since its A-share listing [2]

Group 1 - The agricultural processing sector increased by 0.07% on December 25, with Jiahua Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] - Jiahua Co., Ltd. closed at 16.50, with a rise of 3.84%, and a trading volume of 36,200 shares, amounting to 59.45 million yuan [1] Group 2 - The agricultural processing sector experienced a net outflow of 125 million yuan from main funds, while retail investors saw a net inflow of 116 million yuan [2] - The trading data indicates that Guonong Sugar Industry had a net inflow of 603.67 thousand yuan from main funds, but a net outflow of 737.62 thousand yuan from retail investors [3] - ST Langyuan had a net inflow of 282.36 thousand yuan from main funds, but a significant outflow of 247.49 thousand yuan from retail investors [3]

Group 1 - The company Jia Hua Co., Ltd. reported that as of the end of the third quarter of 2025, the total number of shareholders is 8,539 [2]

山东嘉华生物科技股份有限公司 证券代码：603182 证券简称：嘉华股份 公告编号：2025-034 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 26 日 （星期三） 至 12 月 02 日 （星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 sinoglory@sinoglorygroup.com 进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 山东嘉华生物科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 月 03 日（星期三） 10:00-11:00 举行 2025 年第三季度业绩说明会，就投资者关心的 ...

Core Viewpoint - The company has developed a comprehensive action plan for 2025 aimed at enhancing quality, efficiency, and returns, focusing on its core business of soybean protein and responding to regulatory initiatives to improve the quality of listed companies [1] Group 1: Business Strategy - The company aims to solidify its foundation for high-quality development by focusing on its core business of soybean protein, enhancing operational quality, and optimizing cost control [1][2] - The company is implementing a full-system collaboration model from raw material procurement to sales, ensuring coordinated operations across the supply chain [2] - The company plans to continue enhancing its professional advantages in the soybean protein sector and expand into the plant protein market through technological innovation and product upgrades [2][3] Group 2: Innovation and R&D - The company is committed to an innovation-driven development strategy, focusing on technological advancements and sustainable practices to enhance production efficiency [3][4] - The company has made breakthroughs in key technologies related to soybean protein and is actively collaborating with academic institutions to advance research and development [4] - A systematic intellectual property management system has been established to create technological barriers and enhance overall innovation capabilities [4] Group 3: Investor Relations - The company emphasizes the importance of investor relations management, ensuring timely and accurate information disclosure to protect investor rights [5][6] - Various communication channels have been established to facilitate interaction with investors, including investor meetings and dedicated consultation lines [5][6] - The company has organized investor performance briefings to discuss operational results and financial conditions, maintaining a high response rate to investor inquiries [5][6] Group 4: Corporate Governance - The company is enhancing its internal management controls and decision-making processes to protect the rights of minority shareholders [6][9] - A streamlined and efficient corporate governance structure has been established, ensuring compliance with relevant laws and regulations [6][9] - The company is focused on improving the capabilities of key personnel and enhancing compliance awareness through ongoing training [9] Group 5: Shareholder Returns - The company has a consistent cash dividend policy, having distributed a total of 181.005 million yuan in cash dividends since its listing, representing 41.70% of the total raised funds [7][8] - For the 2024 fiscal year, the company plans to distribute a cash dividend of 0.10 yuan per share, totaling 16.455 million yuan, which is 15.08% of the net profit attributable to shareholders [7][8] - The company aims to maintain a sustainable cash dividend mechanism while balancing operational needs and shareholder returns [8]

Core Viewpoint - The company has announced a comprehensive action plan for 2025 aimed at enhancing quality and efficiency while increasing returns to shareholders [1] Group 1: Strategic Focus - The company will concentrate on its core business to solidify the foundation for high-quality development [1] - Innovation will be a driving force for the development of new productive capacities [1] Group 2: Investor Relations - The company aims to enhance value transmission and deepen communication with investors [1] - There is a commitment to improving investor returns and sharing the results of operational development [1] Group 3: Governance and Accountability - The company plans to optimize its governance system and continuously improve corporate governance [1] - There will be an emphasis on enhancing the capabilities of key personnel and reinforcing accountability [1]

公司代码：603182 公司简称：嘉华股份 公告编号：2025-033 山东嘉华生物科技股份有限公司 关于 2025 年度"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为深入贯彻落实国务院《关于进一步提高上市公司质量的意见》要求，积极响 应上海证券交易所《关于开展沪市公司"提质增效重回报"专项行动的倡议》，贯 彻以投资者为本的发展理念，切实保障和维护投资者合法权益，推进山东嘉华生物 科技股份有限公司（以下简称"公司"）高质量发展和投资价值提升，公司结合实 际经营情况及发展战略，制定了《2025 年度"提质增效重回报"行动方案》（以下 简称"本行动方案"），具体内容如下： 一、聚焦主营业务，夯实高质量发展基础 2025 年，公司锚定"稳健经营、长远发展"战略方向，以大豆蛋白核心主业为 定位，聚焦主营业务深耕与综合实力提升，持续深化蛋白产品功能细分研究和应用 领域拓展，以产品服务为基，以客户市场为导，通过整合产品矩阵、提升服务质量、 优化成本管控、塑造品牌形象等多项举措，全面提升公司运营质效，推 ...